Diseases & Conditions
Grants & Contracts
News & Events
NIAID offers many resources to support your research, including reagents, model organisms, and tissue samples, to name just a few. Use the filters under Filter Search Results to narrow your search, or simply enter specific search terms in the search field.
The Colorado State University Regional Biocontainment Laboratory is one of the NIAID-supported Regional Biocontainment Laboratories.
An overview of the NIAID-supported Duke Human Vaccine Institute (DHVI) Regional Biocontainment Lab (RBL) at The Duke University School of Medicine.
The regional biocontainment laboratory at University of Alabama at Birmingham (UAB), called Southeastern Biosafety Laboratory Alabama Birmingham (SEBLAB), is one of the NIAID-supported Biocontainment Laboratories.
The University of Chicago Howard T. Ricketts Laboratory (HTRL) is one of the NIAID-supported Biocontainment Laboratories. The HTRL is a state of the art BSL-3 facility constructed to support research on bacterial and viral pathogens.
The Regional Biocontainment Lab (RBL) at the Center for Predictive Medicine is one of the NIAID-supported Biocontainment Laboratories.
The University of Missouri Laboratory for Infectious Disease Research (LIDR) is one of the NIAID-supported Biocontainment Laboratories.
The University of Pittsburgh Regional Biocontainment Laboratory is one of the NIAID-supported Biocontainment Laboratories.
The Chemistry Center for Combating Antibiotic-Resistant Bacteria (CC4CARB) is a NIAID-led partnership with RTI International, which oversees the design, synthesis, and management of external investigator-submitted libraries of chemical compounds specifically targeting Gram-negative bacteria.
This contract provides gap-filling support services for HIV prevention drug developers including academic (investigators), for-profit and not-for-profit small and large companies, and other product innovators (henceforth identified as Sponsors) for the development of HIV non-vaccine biomedical pr
The drug screening team at the Integrated Research Facility at Fort Detrick (IRF‑Frederick) can test and characterize the antiviral activity of novel compounds, drugs, and antibodies against multiple viruses in multiple cell lines under a variety of conditions.
This service provides follow-up studies of products which already have been evaluated in a biochemical or cell-based assay and shown to possess an activity profile that warrants further development of the product as an HIV therapeutic.
This service can be used to provide pharmacokinetic and safety assessments of products in mice, rats, rabbits, dogs, and nonhuman primates.
The immunology laboratory at the Integrated Research Facility at Fort Detrick (IRF-Frederick) offers a variety of capabilities to interrogate the immune responses against pathogens requiring maximum containment.
The In Vitro Assessment for Antimicrobial Activity program provides capability in a broad range of in vitro assessments to evaluate promising candidate countermeasures for antimicrobial activity against microbial pathogens and vectors, including those derived from clinical speci
This service provides evaluation of products that have already been evaluated in a biochemical or cell-based assay and shown to possess an activity profile that warrants further development as a microbicide.
The NIAID Centralized Sequencing Program serves as a genomics resource for NIAID human subjects research studies to help address interrelated challenges in clinical care and NIAID Intramural research. Any NIAID participant is eligible to receive genome sequencing and associated services through this protocol.
The primary objective of the response team is to develop and foster overseas relationships through the support of research studies and clinical trials.
The Chemical Countermeasures Research Program (CCRP) supports the discovery and early development of medical countermeasures (MCMs) to treat the acute and/or long-term chronic toxicities after exposure to highly tox
The Throughput Ranking by Iterative Analysis of Genomic Enrichment (TRIAGE) platform is designed to facilitate prediction, analysis, and hypothesis generation from High-throughput genomic studies such as those done by CRISPR, RNAseq, proteomic, and clinical sequencing studies.
The Vaccine Development Services program offers a collection of preclinical services to support the development of vaccines intended for use in the investigation, control, prevention, and treatment of a wide range of infectious agents (other than HIV).
The virology team at the Integrated Research Facility at Fort Detrick (IRF‑Frederick) has extensive expertise working with a range of high‑consequence viral pathogens.